Publications by authors named "Tina Hovey"
Article Synopsis
- - The study aimed to evaluate whether selumetinib combined with radioactive iodine (RAI) improves complete remission rates in patients with high-risk differentiated thyroid cancer compared to RAI alone.
- - In a phase III clinical trial with 400 participants, patients were assigned to receive either selumetinib or a placebo, but results showed no significant improvement in remission rates after 18 months between the two groups.
- - Although selumetinib did not enhance treatment outcomes, it was associated with some adverse effects, primarily dermatitis acneiform, without any treatment-related deaths reported.
Background: In the FLAURA trial, osimertinib demonstrated superior progression-free survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients with EGFR-mutated advanced non-small-cell lung cancer. Patient-reported outcomes from FLAURA are discussed here.
Methods: Patients (N = 556) completed the EORTC QLQ-LC13 weekly for 6 weeks, then every 3 weeks, and the QLQ-C30 every 6 weeks.